Financial Statements
AI Powered Summary
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Ask AI
Consolidated Quarterly Results (in ₹ Crores)
View Standalone
View Standalone
Standalone Profit Loss (in ₹ Crores)
Standalone Balance Sheet (in ₹ Crores)
Standalone Cash Flows (in ₹ Crores)
Documents
Investor Presentation
Q3 FY24
Investor Presentation
Q2 FY24
Investor Presentation
Q1 FY21
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY20
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI


Frequently Asked Questions about Vaishali Pharma Ltd
Vaishali Pharma Ltd (VAISHALI) is currently trading at 6.62 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vaishali Pharma Limited is a pharmaceutical company that deals in formulations, APIs, surgical products, veterinary supplements, and nutraceutical products. The company operates in both domestic and international markets, focusing on API trading locally and marketing a broader range of products abroad. The company has established a strong international presence with over 250 formulation brands across various countries, showcasing a diversified product pipeline and strategic manufacturing collaborations. Vaishali Pharma was recognized as a 'One Star Export House' by the Government of India in 2017, highlighting its export capabilities and significance in international trade. The company holds multiple quality certifications, including ISO 9001:2015, and is linked with certified manufacturing facilities, ensuring high compliance with global standards. Vaishali Pharma's growth includes the launch of a surgical division and venturing into formulation manufacturing and exports, emphasizing its strategic expansion and diversification into new markets and product lines.
Over the past 52 weeks, Vaishali Pharma Ltd has traded between a low of ₹6.50 and a high of ₹15.24. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vaishali Pharma Ltd has a market capitalization of approximately 88.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vaishali Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -2.34 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 88.58 Cr, Vaishali Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vaishali Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vaishali Pharma Ltd is -2.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

